Mobile menu

Alliance Française contre les Maladies Parasitaires


 

  MF Cesbron Delauw

Marie-France
CESBRON-DELAUW

Information

microscope TIMC UMR 5525 CNRS-Université Grenoble-Alpes 
team BNI - Barrières Naturelles et Infectiosité 
location Grenoble
orcid 0000-0002-5423-4094 
email Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser.
website https://www-timc.imag.fr/en/bni

Scientific interests and projects

The BNI team is interested in the innate control of Toxoplasma gondii infectivity.

Infectivity refers to the capacity of a parasite to infect an individual. It involves pathogenrecognition systems, and the diversification of responses relies on the combined genetic diversity of both host and pathogen. We have established that in the rat model the control of Toxoplasma infectivity is genetically controlled by Toxo1, a single locus located on the rat chromosome 10. In resistant rats, the parasite elimination occurs at the site of infection (intestinal barrier) and involves the rapid killing of infected resident macrophages which in turn contributes to the lack of parasite dissemination. In vitro, infected resistant rat macrophages trigger the NOD-like receptor NLRP1a/Caspase-1 pathway to induce the death of both parasites and their hosting macrophages. This is parasite-induced and differs among T. gondii genotypes. Thus, having demonstrated that the parasite fate depends on both the Toxo1 locus genotype (LEW or BN origin) and the parasite genotype, we are interested in the characterization of factor(s) and pathway(s) which activate the Toxo1- dependent resistance to toxoplasmosis.

Our ongoing strategy is based on global comparative analyses of -i) resistant vs susceptible macrophages functions before and following parasite infection and -ii) a set of parasite mutant vs wildtype capable to bypass the resistance. Bioinformatics analysis will combine results from comparative proteomics, transcriptomics and metabolics. Candidate signaling/metabolic host pathway(s) and gene(s) will be validated using classical reverse genetics, biochemical and cellular studies